Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Autologous Cord Blood Stem Cell Infusion Study for Pediatric Acquired Hearing Loss

Also known as: Autologous Stem Cells, Cell based therapy, Autologous hUCB, Cord Blood Registry, NCT02038972

Investigator-led study

Primary source

Sponsor / Institution

Investigator-led study

Program Type

Therapeutic

Modality

Cell Therapy

Stage

Phase 1/2

Status

Completed

Target Gene

—

Route / Mode

Intravenous infusion

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

pediatric, sensorineural, cell-therapy

Trial IDs

Mechanism

Phase 1/2 safety study of a single intravenous infusion of autologous human umbilical cord blood cells in children with acquired sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Verified as a completed investigator-led pediatric autologous cord-blood stem-cell safety study. ClinicalTrials.gov lists CBR Systems as a collaborator but not an industry sponsor; no active commercial hearing-loss cell-therapy program was confirmed in this pass.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT02038972

Open

Key Events

2013-01-01

Registry lists study start for autologous stem-cell infusion in pediatric acquired hearing loss

2017-01-10

Registry lists actual completion of autologous stem-cell infusion study

Clinical Trials (1)